Hosp Pharm. 2022 Feb;57(1):188-192. doi: 10.1177/0018578720985438. Epub 2021 Jan 9.


The increase use of cannabidiol containing products poses potential risks with high-alert medications such as oral anticoagulants. To review the use of cannabidiol and its’ derivatives with oral anticoagulants, searches (2005-May 2020) were performed by PubMed, Google Scholar, and ClinicalTrials.gov. Articles were limited to English-language only. The results yielded 4 case reports evaluating the potential drug interactions between cannabinoids and its’ derivatives and oral anticoagulants. These case reports show the potential for drug interactions when using warfarin and cannabidiol containing products. At time of publication, there were no published articles on drug interactions between cannabidiol and the direct oral anticoagulants. Further research is needed to conclude drug interactions are associated with an increased risk of bleeding or thromboembolic events in these patients.

PMID:35521023 | PMC:PMC9065521 | DOI:10.1177/0018578720985438

Source: ncbi

Partage le savoir
Categories: Medical

error: Content is protected !!